The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

A manufacturing method of an ascorbic acid dispersion material includes a heating step of adding an ascorbic acid into a solvent including one or more selected from the group consisting of glycerin, diglycerin, polyglycerin represented by a following formula, and propylene glycol, and heating the ascorbic acid to a predetermined temperature to dissolve the ascorbic acid; a cooling step of cooling a solution with the ascorbic acid dissolved therein at a cooling rate of 5 to 20° C./min until a temperature of the solution reaches 35 to 50° C. to remove heat from the solution; and a growth step of storing the solution after completion of the cooling step at 27 to 38° C. for a predetermined period to promote crystal growth so that the ascorbic acid crystal has a flat plate shape, a thickness of 0.05 to 3 μm, and an average particle diameter of 50 to 100 μm. ##STR00001##

The present invention includes compounds, compositions comprising the same, and methods using the compounds and/or compositions therein, for modulating skin pigmentation in a mammalian subject. In certain embodiments, the compounds of the invention treat or prevent skin disorders or diseases associated with hyperpigmentation in the subject. In other embodiments, the compounds of the invention act as antagonist to the non-canonical sex steroid hormone receptor GPRE1 and do not bind to a canonical nuclear estrogen receptor (ER). In yet other embodiments, the compounds of the invention comprise acts as agonists to the non-canonical sex steroid hormone receptor PAQR7 and do not bind to a canonical nuclear progesterone receptor (PR).

The present invention includes compounds, compositions comprising the same, and methods using the compounds and/or compositions therein, for modulating skin pigmentation in a mammalian subject. In certain embodiments, the compounds of the invention treat or prevent skin disorders or diseases associated with hyperpigmentation in the subject. In other embodiments, the compounds of the invention act as antagonist to the non-canonical sex steroid hormone receptor GPRE1 and do not bind to a canonical nuclear estrogen receptor (ER). In yet other embodiments, the compounds of the invention comprise acts as agonists to the non-canonical sex steroid hormone receptor PAQR7 and do not bind to a canonical nuclear progesterone receptor (PR).

Provided herein are extracts of sugarcane straw or bagasse, methods of preparing the extracts, and the use of the extracts in compositions that have antioxidant activity, anti-inflammation activity, and antimicrobial activity that can be used as multifunctional ingredients. Further provided are methods of using the extracts to treat or ameliorate conditions involving oxidation, inflammation, skin and food enzymes inhibition activity capacity and microbial growth.

The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.

A method includes administering a cosmetically or dermopharmaceutically effective quantity of exopolysaccharide of a bacterial strain isolated from Pseudoalteromonas sp. with deposit number CNCM I-4150 to at least one of skin, mucous membranes, hair and nails for the treatment and/or care of the skin, mucous membranes, hair and/or nails, and cosmetic and/or dermopharmaceutical compositions including the exopolysaccharide. In particular, the method and composition are suited to treatment of the aging of skin and for the treatment and/or care of disorders, conditions and/or diseases which are a result of a lack or decrease in hydration.

The present application relates to compounds and methods for treating pain, incontinence and other conditions.

The present invention relates to compounds of general formula (I): ##STR00001##
wherein Y, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification. The invention also relates to cosmetic or dermocosmetic composition containing such compounds. The compounds according to the invention are useful as photoprotective agents.

The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit. This study has for the first time shown that a combination of TRIAC and DHEA could effectively stimulate collagen synthesis in skin pretreated with betamethasone valerate demonstrated by an increase in PINP, and that the combination was more effective than TRIAC or DHEA alone. This combination could be used to effectively treat skin atrophy in corticosteroid induced skin atrophy. It could also be used to treat skin atrophy due to other circumstances such as e. g. sun damaged skin and skin atrophy due to high age. Another interesting application would be to combine TRIAC and DHEA with a potent corticosteroid in order to prevent corticosteroid induced skin atrophy. If this combination still is effective in the treatment of eczema and psoriasis and without the risk of skin atrophy this combination will be a major breakthrough for the use of potent topical corticosteroids.